Hills Bank & Trust Co. boosted its position in Pfizer Inc. (NYSE:PFE) by 4.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,365 shares of the biopharmaceutical company’s stock after buying an additional 880 shares during the period. Hills Bank & Trust Co.’s holdings in Pfizer were worth $717,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the company. Catamount Wealth Management increased its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. increased its stake in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the period. Financial Strategy Network LLC purchased a new stake in Pfizer during the first quarter worth approximately $205,000. Oakmont Partners LLC purchased a new stake in Pfizer during the second quarter worth approximately $211,000. Finally, Arete Wealth Advisors LLC increased its stake in Pfizer by 11.3% in the first quarter. Arete Wealth Advisors LLC now owns 7,172 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 726 shares during the period. 69.65% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE:PFE) traded up 1.65% during trading on Friday, reaching $33.87. The company’s stock had a trading volume of 28,593,974 shares. The company has a market capitalization of $205.44 billion, a PE ratio of 30.03 and a beta of 0.87. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The company has a 50 day moving average price of $34.48 and a 200-day moving average price of $34.04.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same period last year, the firm earned $0.56 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.54%. Pfizer’s payout ratio is 95.24%.
A number of equities research analysts recently commented on the company. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.08 target price for the company in a report on Tuesday, August 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $54.00 target price on shares of Pfizer in a report on Monday, June 27th. TheStreet raised Pfizer from a “hold” rating to a “strong-buy” rating in a report on Friday, June 3rd. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $40.00 target price on shares of Pfizer in a report on Thursday, July 21st. Ten research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.